Pharmacological basis of β-lactamase inhibitor therapeutics: Tazobactam in combination with ceftolozane

导出原文传递

翻译打印收藏纠错

作者： VanScoy,B. ^[1] ; Mendes,R.E. ^[2] ; McCauley,J. ^[3] ; Bhavnani,S.M. ^[4] ; Bulik,C.C. ; Okusanya,O.O. ; Forrest,A. ; Jones,R.N. ; Friedrich,L.V. ; Steenbergen,J.N. ; Ambrose,P.G.

作者单位： JMI Laboratories, North Liberty, IA, United States ^[1] Institute for Clinical Pharmacodynamics, Latham, NY, United States, University of Oxford, Oxford ^[2] Cubist Pharmaceuticals, Lexington, MA, United States ^[3] Institute for Clinical Pharmacodynamics, Latham, NY, United States ^[4]

发布时间 2014-04-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Antimicrobial Agents and Chemotherapy

2013年57卷12期

5924-5930页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Pharmacological basis of β-lactamase inhibitor therapeutics: Tazobactam in combination with ceftolozane

Antimicrobial Agents and Chemotherapy

相似文献

Antimicrobial Agents and Chemotherapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Pharmacological basis of β-lactamase inhibitor therapeutics: Tazobactam in combination with ceftolozane

Antimicrobial Agents and Chemotherapy

相似文献

Antimicrobial Agents and Chemotherapy

相关期刊

检索历史清除